---
title: "301211.SZ (301211.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/301211.SZ/news.md"
symbol: "301211.SZ"
name: "301211.SZ"
parent: "https://longbridge.com/en/quote/301211.SZ.md"
datetime: "2026-03-10T00:29:42.559Z"
locales:
  - [en](https://longbridge.com/en/quote/301211.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/301211.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/301211.SZ/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/301211.SZ/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/301211.SZ/news.md)


# 301211.SZ (301211.SZ) — Related News

### [BIOCAUSE HEILEN PHARMA: Shareholder Lei Xiaoyan has reduced her holdings by 0.998%](https://longbridge.com/en/news/276732931.md)
*2026-02-24T12:27:29.000Z*
> BIOCAUSE HEILEN PHARMA announced that shareholder Lei Xiaoyan will reduce holdings of 4.1671 million shares through cent

### [BIOCAUSE HEILEN PHARMA: The application for the listing of the chemical raw material drug, Hydrochloride of Alectinib, has been approved](https://longbridge.com/en/news/274618061.md)
*2026-02-03T07:59:05.000Z*
> BIOCAUSE HEILEN PHARMA recently announced that the marketing application for the chemical raw material drug, Erlotinib H

### [BIOCAUSE HEILEN PHARMA: Passed the on-site inspection by the U.S. FDA](https://longbridge.com/en/news/273668698.md)
*2026-01-26T08:04:02.000Z*
> Hubei BIOCAUSE HEILEN PHARMA Co., Ltd. underwent a routine inspection by the U.S. Food and Drug Administration (FDA) for

### [BIOCAUSE HEILEN PHARMA: Expected to see a year-on-year decline of 66.14%-57.40% in net profit attributable to the parent company in 2025](https://longbridge.com/en/news/272377874.md)
*2026-01-13T08:02:16.000Z*
> On January 13th, BIOCAUSE HEILEN PHARMA announced that it expects a net profit attributable to the parent company of RMB

### [The influenza sector rebounded in the closing hours](https://longbridge.com/en/news/267636200.md)
*2025-11-27T06:41:01.000Z*
> The influenza sector rebounded in the closing hours, with TY PHAR. hitting the daily limit, and GDK Biotech, PKU HEALTHC

### [](https://longbridge.com/en/news/267266437.md)
*2025-11-25T01:57:01.000Z*
> The A-share influenza concept quickly surged, with PKU HEALTHCARE hitting the daily limit, GDK Biotech rising over 10%, 

### [](https://longbridge.com/en/news/267095859.md)
*2025-11-24T01:37:50.000Z*
> The A-share vitamin sector fluctuated and strengthened in early trading, with MEDISAN hitting the daily limit, GOLDSTONE

### [](https://longbridge.com/en/news/265255644.md)
*2025-11-11T03:11:49.000Z*
> The A-share large pharmaceutical sector rebounded, with chemical pharmaceuticals, innovative drugs, weight loss drugs, a